Ipilimumab, nivolumab, and brentuximab vedotin combination therapies in patients with relapsed or refractory Hodgkin lymphoma: phase 1 results of an open-label, multicentre, phase 1/2 trial

Publication date: September 2020Source: The Lancet Haematology, Volume 7, Issue 9Author(s): Catherine S Diefenbach, Fangxin Hong, Richard F Ambinder, Jonathon B Cohen, Michael J Robertson, Kevin A David, Ranjana H Advani, Timothy S Fenske, Stefan K Barta, Neil D Palmisiano, Jakub Svoboda, David S Morgan, Reem Karmali, Elad Sharon, Howard Streicher, Brad S Kahl, Stephen M Ansell

Source: The Lancet Haematology - August 25, 2020 Category: Hematology Source Type: research